Gabather AB (publ) - Asset Resilience Ratio
Gabather AB (publ) (GABA) has an Asset Resilience Ratio of 82.06% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See GABA current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how Gabather AB (publ)'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Gabather AB (publ) total assets.
Liquid Assets Composition Over Time
This chart breaks down Gabather AB (publ)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Gabather AB (publ) (GABA) total liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr3.14 Million | 82.06% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr3.14 Million | 82.06% |
Asset Resilience Insights
- Very High Liquidity: Gabather AB (publ) maintains exceptional liquid asset reserves at 82.06% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Gabather AB (publ) Industry Peers by Asset Resilience Ratio
Compare Gabather AB (publ)'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Kamada
TA:KMDA |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.48% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 4.31% |
|
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723 |
Drug Manufacturers - Specialty & Generic | 1.01% |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL |
Drug Manufacturers - Specialty & Generic | 5.90% |
Annual Asset Resilience Ratio for Gabather AB (publ) (2016–2025)
The table below shows the annual Asset Resilience Ratio data for Gabather AB (publ).
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 82.06% | Skr3.14 Million ≈ $338.24K |
Skr3.83 Million ≈ $412.17K |
+34.16pp |
| 2024-12-31 | 47.90% | Skr878.00K ≈ $94.49K |
Skr1.83 Million ≈ $197.26K |
+32.76pp |
| 2023-12-31 | 15.14% | Skr1.11 Million ≈ $119.99K |
Skr7.36 Million ≈ $792.48K |
-77.75pp |
| 2022-12-31 | 92.89% | Skr6.27 Million ≈ $674.97K |
Skr6.75 Million ≈ $726.62K |
-3.57pp |
| 2021-12-31 | 96.46% | Skr14.85 Million ≈ $1.60 Million |
Skr15.39 Million ≈ $1.66 Million |
+0.32pp |
| 2020-12-31 | 96.14% | Skr30.92 Million ≈ $3.33 Million |
Skr32.16 Million ≈ $3.46 Million |
-1.32pp |
| 2019-12-31 | 97.46% | Skr44.90 Million ≈ $4.83 Million |
Skr46.07 Million ≈ $4.96 Million |
+5.79pp |
| 2018-12-31 | 91.67% | Skr16.65 Million ≈ $1.79 Million |
Skr18.16 Million ≈ $1.95 Million |
+15.40pp |
| 2017-12-31 | 76.27% | Skr36.74 Million ≈ $3.95 Million |
Skr48.18 Million ≈ $5.18 Million |
-4.14pp |
| 2016-12-31 | 80.41% | Skr27.94 Million ≈ $3.01 Million |
Skr34.75 Million ≈ $3.74 Million |
-- |
About Gabather AB (publ)
Gabather AB (publ), a pharmaceutical company, develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics, anti-depressants and anxiolytics, and analgesics, as well as cognition-enhancing treatments, including Alzheimer's disease. The company focuses on developing GT-002, a pro-cognitive drug candidate for the treatment … Read more